Target intelligence / Profile preview

Escherichia coli heat-labile enterotoxin B subunit (LT-B)

Target
LT-B
Molecular classification
Bacterial toxin subunit, AB5 toxin family, Oligomeric binding protein, Membrane-binding protein
01

Overview

The Escherichia coli heat-labile enterotoxin B subunit is one of five identical binding subunits forming the pentameric ring of the heat-labile AB5 enterotoxin. This subunit is responsible for the high-affinity binding of the toxin complex to GM1 gangliosides on the surface of mammalian cells, enabling entry of the enzymatically active A subunit. The B subunit has no enzymatic activity but is essential for pathogenesis, as well as for its potent capacity to serve as a research and clinical adjuvant. Recombinant LT-B, lacking the toxic activity of the A subunit, is being explored for its ability to modulate immune responses, induce regulatory T cells, and act as a carrier or platform for antigens in vaccines. Its structure and function are closely related to the cholera toxin B subunit, but it has antigenic distinctions and unique binding properties.

Other names
LT-BETxBLTB subunitE. coli enterotoxin B subunit
02

Mechanism of action

Binds GM1 ganglioside receptors in host cell membranes, allowing uptake of the whole AB5 toxin complex. When used as an adjuvant or delivery tool, facilitates antigen uptake and T cell activation.

03

Biological functions

Membrane binding to GM1 ganglioside receptorsMediates cellular uptake of the toxin complexAdjuvant activity (enhances immune responses)Protein/antigen delivery platform in vaccinesImmunomodulation, including induction of regulatory T cells
04

Disease associations

Infection (causes ETEC-induced diarrhea)Immunomodulation in autoimmune and allergic disease models
05

Safety considerations

Use of wild-type protein carries risk of toxin-related diarrhea; recombinant or mutated forms lacking A subunit toxicity are preferred for research and therapeutic applicationsPotential immunogenicity when used as a vaccine adjuvant
06

Biomarkers

Presence of antibodies against LT-B (as evidence of ETEC infection)

Beyond the preview

Go deeper on Escherichia coli heat-labile enterotoxin B subunit (LT-B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escherichia coli heat-labile enterotoxin B subunit (LT-B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call